Prevalence of use and acute toxicity associated with the use of NBOMe drugs

Clinical Toxicology

Volumn 53, Issue 2, 2015, Pages 85-92

  Wood, David M ^a,b   Sedefov, Roumen ^c   Cunningham, Andrew ^c   Dargan, Paul I ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Acute toxicity; NBOMe; Novel psychoactive substances; Recreational drugs

Indexed keywords

N 2 METHOXYBENZYL DERIVATIVE; PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG; [2 (2,5 DIMETHOXYPHENYL)N(2 METHOXYBENZYL)ETHANAMINE]; [2 (BROMO 2,5 DIMETHOXYPHENYL)N(2 METHOXYBENZYL)ETHANAMINE]; [2 (CHLORO 2,5 DIMETHOXYPHENYL)N[(2 METHOXYPHENYL)METHYL]ETHANAMINE]; [4 IODO 2,5 DIMETHOXY N(2 METHOXYBENZYL)PHENETHYLAMINE]; DESIGNER DRUG;

ACUTE KIDNEY FAILURE; ACUTE TOXICITY; AGGRESSION; AGITATION; ARTICLE; DRUG FATALITY; DRUG USE; FINLAND; HUMAN; HUNGARY; HYPERTENSION; HYPERTHERMIA; ITALY; MEDLINE; NORWAY; POLAND; PREVALENCE; RISK ASSESSMENT; SEIZURE; SPAIN; TACHYCARDIA; ADULT; DRUG EFFECTS; FEMALE; HEMODYNAMICS; INFORMATION PROCESSING; MALE; POISON CENTER; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADULT; DATA COLLECTION; DESIGNER DRUGS; FEMALE; HEMODYNAMICS; HUMANS; MALE; PHENETHYLAMINES; POISON CONTROL CENTERS; PREVALENCE; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84922981774     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1004179     Document Type: Article

References (40)

1. UNODC. The challenge of the New Psychoactive Substances. Available at: http://wwwunodcorg/documents/scientific/NPS-2013-SMARTpdf 2013. (last accessed 1st October 2014)
2. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2014. Available at: http://wwwemcddaeuropaeu/edr2014. (last accessed 1st October 2014)
3. EMCDDA. Risk Assessment Report of a new psychoactive substance: 2-(4-iodo-2,4-dimethoxyphenyl)-N-(2-methoxybenzy)ethanamine (25I-NBOMe). Available at: http://wwwemcddaeuropaeu/publications/risk-assessment/25I-NBOMe. (last accessed 1st October 2014)
4. Abstracts of the 2010 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 11-14 May 2010, Bordeaux, France. Clin Toxicol (Phila) 2010; 48: 240-318.
5. Abstracts of the 2011 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 24-27 May 2011, Dubrovnik, Croatia. Clin Toxicol (Phila) 2011; 49: 197-269.
6. Abstracts of the 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 25 May-1 June 2012, London, UK. Clin Toxicol (Phila) 2012; 50: 273-366.
7. XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 28-31 May 2013, Copenhagen, Denmark. Clin Toxicol (Phila) 2013; 51: 252-378.
8. XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 27-30 May 2014, Brussels, Belgium. Clin Toxicol (Phila) 2014; 52: 295-443.
9. Abstracts of the 2010 North American Congress of Clinical Toxicology Annual Meeting, October 7-12, 2010, Denver, CO, USA. Clin Toxicol (Phila) 2010; 48: 604-667.
10. Abstracts of the 2011 North American Congress of Clinical Toxicology Annual Meeting, September 21-26, Washington, DC, USA. Clin Toxicol (Phila) 2011; 49: 515-627.
11. Annual Meeting of the North American Congress of Clinical Toxicology (NACCT) October 1-6, 2012 Las Vegas, NV, USA. Clin Toxicol (Phila) 2012; 50: 574-720.
12. Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin Toxicol (Phila) 2013; 51: 575-724.
13. European Information System and Database on New Drugs (EDND). Available at: https://ednd-cmaemcddaeuropaeu/(last accessed 1st October 2014)
14. Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 2014; 32: 105-115.
15. DEA. U.S. Drug Enforcement Administration, Offi ce of Diversion Control: National Forensic Laboratory Information System: Midyear Report 2013. Springfield, VA: US Drug Enforcement Administration. 2014. (last accessed 1st October 2014)
16. UNODC-EWA: 25I-NBOMe is the most reported substance in 2014. Available at: https://www.unodc.org/LSS/Announcement/Details/f6acf081-dd51-4d23-9c66-d01eeef5cbf9 (last accessed 1st October 2014).
17. European Monitoring Centre for Drugs and Drug Addiction. Early Warning System. Available at: http://wwwemcddaeuropaeu/themes/new-drugs/early-warning. (last accessed 1st October 2014).
18. Lawn W, Barratt M, Williams M, Horne A, Winstock A. T he NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014; 28: 780-788.
19. Lovett CJ, Measham F, Dargan PI, Wood DM. Awareness and use of the NBOMe novel psychoactive substances is lower than those of mephedrone in a high drug using population. Clin Toxicol (Phila) 2014; 52: 361.
20. Moore K, Dargan PI, Wood DM, Measham F. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res 2013; 19: 276-282.
21. Wood DM, Hunter L, Measham F, Dargan PI. Limited use of novel psychoactive substances in South London nightclubs. QJM 2012; 105: 959-964.
22. Wood DM, Measham F, Dargan PI. 'Our favourite drug': prevalence of use and preference for mephedrone in the London night time economy one year afer control. J Subs Use 2012; 68: 853-856.
23. Earth and Fire Erowid. Spotlight on NBOMes: Potent Psychedelic Issues. Erowid Extracts. 2013; 24: 2-5.
24. Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol (Phila) 2014; 52: 561-565.
25. Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 2014; 6: 764-769.
26. Grautoff S, Kahler J. [Near fatal intoxication with the novel psychoactive substance 25C-NBOMe]. Med Klin Intensivmed Notfallmed 2014; 109: 271-275.
27. Nefcy A, Wilson J, Smith MP, Maso K, Bora K. Which reality is this? A novel PCP analog combined with 2C-NBOMe causes a dissociative serotonin syndrome. Clin Toxicol (Phila) 2013; 51: 665.
28. Armenian P, Gerona RR. The electric Kool-Aid NBOMe test: LCTOF/MS confi rmed 2C-C-NBOMe (25C) intoxication at Burning Man. Am J Emerg Med. Epub ahead of print 26 Apr 2014 [DOI: 10.1016/j.ajem.2014.04.047]
29. Armenian P, Gerona RR. The electric koolaid NBOMe test: LC-TOF/MS confi rmed 2C-C-NBOMe (25C) intoxication at Burning Man. Clin Toxicol (Phila) 2014; 52: 363-364.
30. Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25INBOMe): clinical case with unique confirmatory testing. J Med Toxicol 2014; 10: 45-50.
31. Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 2013; 51: 487-492.
32. Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 2013; 51: 174-177.
33. Rose SR, Cumpston KL, Stromberg PE, Wills BK. Severe poisoning following self-reported use of 25-I, a nove substituted amphetamine. Clin Toxicol (Phila) 2012; 50: 707-708.
34. Poklis JL, Charles J, Wolf CE, Poklis A. High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed Chromatogr 2013; 27: 1794-1800.
35. Kelly A, Eisnga B, Riley B, Judge B. Case series of 25I-NBOMe exposures with laboratory confirmation. Clin Toxicol (Phila) 2012; 50: 702.
36. Forrester MB. NBOMe designer drug exposures reported to Texas poisons centers. J Addict Dis 2014; 33: 196-201.
37. Ralston N, Davies L. Teen jumps to his death after $ 1.50 drug hit 2013. Available from: http://www.smh.com.au/nsw/teen-jumps-to-his-death-after-150-drug-hit-20130606-2nrpe.html#ixzz35BP7Ymmx. (last accessed 1st October 2014).
38. Caldicott DG, Bright SJ, Barratt MJ. NBOMe - a very different kettle of fi sh. Med J Aust 2013; 199: 322-323.
39. Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A. Postmortem detection of 25I-NBOMe [2-(4-iodo-2, 5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 2014; 234: e14-20.
40. Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA. Pathological fi ndings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 2014; 35: 20-25.